var data={"title":"Lithium: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lithium: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6472?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">see &quot;Lithium: Drug information&quot;</a> and <a href=\"topic.htm?path=lithium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lithium: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709018\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Monitoring:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520178\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lithobid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189344\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Lithium Carbonate;</li>\n      <li>Carbolith;</li>\n      <li>Lithane;</li>\n      <li>Lithmax;</li>\n      <li>PMS-Lithium Carbonate;</li>\n      <li>PMS-Lithium Citrate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053683\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidepressant, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antimanic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053675\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">see &quot;Lithium: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Monitor serum concentrations and clinical response (efficacy and toxicity) to determine proper dose. Each 5 mL of lithium citrate oral solution contains 8 mEq of lithium ion, equivalent to the amount of lithium in 300 mg of lithium carbonate immediate release capsules/tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Bipolar Disorder:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Oral: Children &ge;6 year and Adolescents: Limited data available in ages &lt;12 years: <b>Note: </b>Dosing in patients 6 years of age extrapolated from clinical experience (Kliegman 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &lt;30 kg: Initial: 300 mg twice daily, increase dose at weekly intervals in 300 mg/day increments to clinical response and as tolerated (including serum lithium concentration &le;1.4 mEq/L) up to a weight-dependent maximum daily dose: Patients &lt;23 kg: 900 mg/<b>day</b>; patients &ge;23 kg: 40 mg/kg/<b>day. </b>In a multicenter, double-blind, placebo-controlled efficacy trial for treatment of acute mania, the mean effective daily dose was 956 &plusmn; 225 mg/<b>day</b>. For all patients in the trial (regardless of weight) the mean final dose was: 30.5 &plusmn; 8.7 mg/kg/day. For maintenance therapy (long-term), doses were titrated to maintain the target serum trough concentration of 0.8 to 1.2 mEq/L as tolerated (Findling 2011; Findling 2013; Findling 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient weight &ge;30 kg: Initial: 300 mg 3 times daily; during first week of therapy (midweek), may increase dose by 300 mg/day; then continue to increase dose at weekly intervals in 300 mg/day increments to clinical response and as tolerated (including serum lithium concentration &le;1.4 mEq/L) not to exceed a maximum daily dose of: 40 mg/kg/<b>day. </b>In a multicenter, double-blind, placebo-controlled efficacy trial for treatment of acute mania, the mean effective daily dose was 1,583 &plusmn; 524 mg/<b>day</b>. For all patients in the trial (regardless of weight) the mean final dose was 30.5 &plusmn; 8.7 mg/kg/day. For maintenance therapy (long-term), doses were titrated to maintain the target serum trough concentration of 0.8 to 1.2 mEq/L as tolerated (Findling 2011; Findling 2013; Findling 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Oral: Children &ge;12 years and Adolescents: Weight-based usual daily dosing administered in 2 divided doses: &lt;22 kg: 600 mg/day; 22 to 41 kg: 900 mg/day, and &gt;41 kg: 1,200 mg/day (Kliegman 2016). In an open-label trial of 27 subjects (age range: 12 to 18 years), an initial dose of 15 mg/kg/dose twice daily, maximum initial dose: 600 mg/dose, with dose titration at weekly intervals as tolerated to target serum lithium concentration of 1 to 1.2 mEq/L was used (Patel 2006) In adults, therapy is initiated at a low dose (eg, 450 mg 2 times daily or less); increased gradually based on response and tolerability (APA 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Bipolar disorder (acute mania and maintenance): </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: Initiate at low dose (eg, 300 mg 3 times daily or less); increase gradually based on response and tolerability (APA 2002); usual dosage: 900 to 1,800 mg daily in 3 to 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initiate at low dose (eg, 450 mg 2 times daily or less); increase gradually based on response and tolerability (APA 2002); usual dosage: 900 to 1,800 mg daily in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 50 mL/minute: Administer 50% to 75% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer 25% to 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End stage renal disease (ESRD) with hemodialysis: Dose after dialysis (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment</b>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189316\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as carbonate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg, 300 mg, 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as citrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 8 mEq/5 mL (5 mL [DSC], 500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as carbonate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as carbonate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lithobid: 300 mg [contains fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg, 450 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189302\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053688\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with meals to decrease GI upset. Do not crush or chew extended release dosage form; swallow whole</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25226298\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Store between 15&deg;C and 30&deg;C (59&deg;F to 86&deg;F). Protect tablets and capsules from moisture. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053687\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of acute manic episodes (FDA approved in ages &ge;12 years and adults); maintenance treatment of mania in individuals with bipolar disorder (FDA approved in ages &ge;12 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189394\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">Eskalith may be confused with Estratest </p>\n        <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">Lithium may be confused with lanthanum, Ultram</p>\n        <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">Lithobid may be confused with Levbid, Lithostat</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Do not confuse <b>mEq</b> (milliequivalent) with <b>mg</b> (milligram). <b>Note:</b> 300 mg lithium carbonate or citrate contain 8 mEq lithium. Dosage should be written in <b>mg</b> (milligrams) to avoid confusion. </p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Check prescriptions for unusually high volumes of the syrup for dosing errors.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189392\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Abnormal T waves on ECG, bradycardia, cardiac arrhythmia, chest tightness, circulatory shock, cold extremities, edema, hypotension, myxedema, sinus node dysfunction, startled response, syncope </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Ataxia, blackout spells, cogwheel rigidity, coma, confusion, dizziness, drowsiness, dystonia, EEG pattern changes, extrapyramidal reaction, fatigue, hallucination, headache, hyperactive deep tendon reflex, hypertonia, involuntary choreoathetoid movements, lethargy, local anesthesia, memory impairment, loss of consciousness, metallic taste, myasthenia gravis (rare), pseudotumor cerebri, psychomotor retardation, reduced intellectual ability, restlessness, salty taste, sedation, seizure, slowed intellectual functioning, slurred speech, stupor, tics, vertigo, worsening of organic brain syndromes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, blue-gray skin pigmentation, dermal ulcer, dry or thinning of hair, exacerbation of psoriasis, folliculitis, pruritus, psoriasis, skin rash, xerosis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Albuminuria, dehydration, diabetes insipidus, euthyroid goiter, glycosuria, hypercalcemia (secondary to hyperparathyroidism [McKnight 2012]), hyperglycemia, hyperparathyroidism, hyperthyroidism, hypothyroidism, increased radioactive iodine uptake, increased thirst, polydipsia, weight gain, weight loss </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, dental caries, diarrhea, dysgeusia, dyspepsia, excessive salivation, flatulence, gastritis, nausea, sialadenitis, sialorrhea, swelling of lips, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence, incontinence, oliguria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukocytosis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Joint swelling, muscle hyperirritability, neuromuscular excitability, polyarthralgia, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, exophthalmos, nystagmus, transient scotoma </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Decreased creatinine clearance, polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189324\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to lithium or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Immediate-release capsule, solution and tablet: Severe cardiovascular or renal disease, severe debilitation, dehydration, sodium depletion, concurrent use with diuretics</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189306\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, lithium has been determined to be an agent that may cause direct myocardial toxicity that is reversible upon discontinuation (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia: Hypercalcemia with or without hyperparathyroidism has been reported. Risks are greater in women and possibly in older patients; symptom onset does not appear to be related to therapy duration (Lehmann 2013).  Serum calcium levels typically range from slightly above normal to over 15 mg/dL and PTH levels may range from high normal to several times the upper limit of normal (Lehmann 2013); magnesium levels are often elevated; serum phosphate levels may be either normal or low (Grandjean 2009). Monitor calcium and PTH levels as clinically indicated. Consider discontinuation if clinical manifestations of hypercalcemia are present (fatigue, weakness, abdominal pain, constipation, nephrolithiasis, bone pain) or if calcium levels are &gt;11.4 mg/dL.  Following discontinuation, check serum calcium levels weekly for one month for return to baseline. Changes are usually reversible if lithium is discontinued; however, sustained hypercalcemia and parathyroid gland enlargement has been reported (Lehmann 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypothyroidism: May cause hypothyroidism, generally within 6 to 18 months of initiating treatment. Women may be at an increased risk. If hypothyroidism develops and symptoms of bipolar disorder are well-controlled, consider continuing lithium and treating hypothyroidism (APA 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: Chronic therapy results in diminished renal concentrating ability (nephrogenic diabetes insipidus); this is usually reversible when lithium is discontinued. Monitor for changes in renal function and avoid dehydration; re-evaluation of treatment may be necessary. Morphologic changes with glomerular and interstitial fibrosis and nephron atrophy have been reported in patients on chronic lithium therapy; morphologic changes have also been reported in patients with bipolar disorder never exposed to lithium. The relationship between morphologic changes and renal function, and the association with lithium therapy, have not been established. If polyuria develops during lithium therapy, consolidating to once-daily dosing may decrease urine output (APA 2002; Carter 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Generally avoid use in patients with significant cardiovascular disease due to an increased risk of lithium toxicity; if use is unavoidable, use with extreme caution and monitor serum lithium levels closely. Lithium may unmask Brugada syndrome; avoid use in patients with or suspected of having Brugada syndrome. Consult with a cardiologist if a patient is suspected of having Brugada syndrome or has risk factors for Brugada syndrome (eg, unexplained syncope, a family history of Brugada syndrome, a family history of sudden death before the age of 45 years), or if unexplained syncope or palpitations develop after starting therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dehydration: Generally avoid use in patients with significant fluid loss or sodium depletion due to an increased risk of lithium toxicity. If use is unavoidable, use extreme caution and monitor serum lithium levels closely. Decreased tolerance to lithium has been reported with sweating or diarrhea and, if such occur, supplemental fluid and salt should be administered under careful medical supervision and lithium intake reduced or suspended until the condition is resolved. In addition, concomitant infection with elevated temperatures may also necessitate a temporary reduction or cessation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression/suicidal ideation: Use with caution in patients at risk of suicide (suicidal thoughts or behavior) by drug overdose; lithium has a narrow therapeutic index (APA 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Generally avoid use in patients with significant renal disease due to an increased risk of lithium toxicity. If use is unavoidable, use extreme caution and monitor serum lithium levels closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Use with caution in patients with thyroid disease; hypothyroidism may occur with treatment (APA 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated: Generally avoid use in severely debilitated patients due to an increased risk of lithium toxicity; if use is unavoidable, use extreme caution and monitor serum lithium levels closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly patients due to an increased risk of lithium toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute manic phase: Higher serum concentrations may be required and tolerated during an acute manic phase; however, the tolerance decreases when symptoms subside.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lithium toxicity: <b>[US Boxed Warning]: Lithium toxicity is closely related to serum concentrations and can occur at  doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy.</b> Normal fluid and salt intake must be maintained during therapy. Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or dehydration, or sodium depletion due to risk of lithium toxicity; if use is unavoidable, lithium may be undertaken with extreme caution, including frequent serum lithium determinations and possibly hospitalization. Discontinue therapy if such clinical signs of lithium toxicity occur (eg, diarrhea, vomiting, tremor, mild ataxia, drowsiness, or muscular weakness).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48857646\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric patients, lithium is associated with not only a significant increased incidence of TSH elevation but also a significant elevation of the TSH concentrations; one trial where patients received both lithium and valproic acid reported an incidence of 24% (20 out of 82 patients); onset was observed to be within first 3 months of therapy and was reversible upon dose decrease or discontinuation of lithium; monitor thyroid function with initiation of therapy and periodically or if signs of hypothyroidism develop (Findling 2011; Findling 2015; Gracious 2004). Although the manufacturer does not define frequency of adverse reactions, a pediatric efficacy trial (age range: 7 to 17 years) reported the most frequent adverse reactions as vomiting (45% to 55%), nausea (43% to 67%) and headache (36% to 65%) (Findling 2011; Findling 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299613\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189311\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12559&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Lithium may diminish the stimulatory effect of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May increase the serum concentration of Lithium. Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May increase the serum concentration of Lithium. Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Lithium may enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine and Caffeine Containing Products: May decrease the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitonin: May decrease the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination.<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: May decrease the serum concentration of Lithium. Management: Consider separating administration of lithium from administration of oral calcium polystyrene sulfonate by at least 6 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May enhance the adverse/toxic effect of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: May decrease the serum concentration of Lithium.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Lithium may diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May enhance the adverse/toxic effect of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methyldopa: May enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Lithium. MetroNIDAZOLE (Systemic) may increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Lithium. Management: This combination should be undertaken with great caution.  When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome.<b> Exceptions: </b>Moclobemide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Lithium may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Lithium.<b> Exceptions: </b>Sulindac.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May enhance the adverse/toxic effect of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Iodate: Lithium may enhance the hypothyroid effect of Potassium Iodate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Iodide: May enhance the hypothyroid effect of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: May enhance the adverse/toxic effect of Lithium. Specifically, the myeloproliferative effects may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: Lithium may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.  Management: This combination should be undertaken with great caution.  When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Bicarbonate: May increase the excretion of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Chloride: May increase the excretion of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: May decrease the serum concentration of Lithium. Management: Consider separating administration of lithium from administration of oral sodium polystyrene sulfonate by at least 6 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: May decrease the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May decrease the excretion of Lithium.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Lithium may enhance the neurotoxic effect of Tricyclic Antidepressants.  Management: This combination should be undertaken with great caution.  When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189312\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189327\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Lithium crosses the placenta in concentrations similar to those in the maternal plasma (Newport 2005). Cardiac malformations in the infant, including Ebstein anomaly, are associated with use of lithium during the first trimester of pregnancy. Other adverse events including polyhydramnios, fetal/neonatal cardiac arrhythmias, hypoglycemia, diabetes insipidus, changes in thyroid function, premature delivery, floppy infant syndrome, or neonatal lithium toxicity are associated with lithium exposure when used later in pregnancy (ACOG 2008). The incidence of adverse events may be associated with higher maternal doses (Newport 2005). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Due to pregnancy-induced physiologic changes, women who are pregnant may require dose adjustments of lithium to achieve euthymia and avoid toxicity (ACOG 2008; Grandjean 2009; Yonkers 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For planned pregnancies, use of lithium during the first trimester should be avoided if possible (Grandjean 2009). If lithium is needed during pregnancy, the minimum effective dose should be used, maternal serum concentrations should be monitored, and consideration should be given to start therapy after the period of organogenesis; lithium should be suspended 24 to 48 hours prior to delivery or at the onset of labor when delivery is spontaneous, then restarted when the patient is medically stable after delivery (ACOG 2008; Grandjean 2009; Newport 2005). Fetal echocardiography should be considered if first trimester exposure occurs (ACOG 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053682\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum concentrations (see Reference Range), renal function including BUN and SrCr (baseline, every 2 to 3 months during the first 6 months of treatment, then at least once a year in stable patients or as clinically indicated; pediatric patients may require more frequency); serum electrolytes (baseline, then periodically), serum calcium (baseline, 2 to 6 weeks after initiation, then every 6 to 12 months; repeat as clinically indicated) (Broome 2011); thyroid function (baseline, 1 to 2 times with in the first 6 months of treatment, then periodically in stable patients or as clinically indicated); beta-hCG pregnancy test for all females of child-bearing age not known to be sterile (baseline); ECG with rhythm strip (baseline for all patients over 40 years, repeat as clinical indicated), CBC with differential (baseline, repeat as clinically indicated); weight (baseline, then periodically) (APA 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053686\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum lithium concentrations: Timing of serum samples: Draw trough just before next dose (8 to 12 hours after previous dose)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;6 years and Adolescents: The first week of therapy, evaluate levels twice followed by once weekly monitoring until patient's clinical status and levels are stable (Findling 2011; Findling 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Twice weekly until both patient&rsquo;s clinical status and levels are stable, then repeat levels every 1 to 3 months or as clinically indicated) (APA 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric: Limited data available: Children &ge;6 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute mania was 0.6 to 1.2 mEq/L (SI: 0.6 to 1.2 mmol/L) has been suggested and used in clinical trials (Findling 2011; Geller 2012; Kliegman 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance 0.6 to 0.9 mEq/L (0.6 to 0.9 mmol/L) (Kliegman 2016); in one trial, a higher range of 0.8 to 1.2 mEq/L (0.8 to 1.2 mmol/L) has also been used (Findling 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult: Acute mania: 0.5 to 1.2 mEq/L (SI: 0.5 to 1.2 mmol/L); and maintenance: 0.6 to 1 mEq/L (SI: 0.6 to 1 mmol/L); a higher rate of relapse is described in subjects who are maintained &lt;0.4 mEq/L (SI: &lt;0.4 mmol/L) (APA 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toxic: &gt;1.5 mEq/L (SI: &gt;1.5 mmol/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189305\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">The precise mechanism of action in mood disorders is unknown. Traditionally thought to alter cation transport across cell membranes in nerve and muscle cells, influence the reuptake of serotonin and/or norepinephrine, and inhibit second messenger systems involving the phosphatidylinositol cycle (Ward, 1994).  May also provide neuroprotective effects by increasing glutamate clearance, inhibiting apoptotic glycogen synthase kinase activity, increasing the levels of antiapoptotic protein Bcl-2 and, enhancing the expression of neurotropic factors, including brain-derived neurotrophic factor (Sanacora 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189323\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: Initial: 0.307 L/kg; V<sub>dss</sub>: 0.7 to 1 L/kg; decreased in elderly patients (Ward 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Not protein bound</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Not metabolized (Ward 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 80% to 100% (Ward 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients 7 to 17 years: t<sub>1/2(beta)</sub>: 27 hours (Findling 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 18 to 36 hours; prolonged in elderly patients (~28.5 hours) (Ward 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Immediate release: ~0.5 to 3 hours; Extended release: 2 to 6 hours; Solution: 15 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily; unchanged drug); sweat, saliva, and feces (negligible amounts)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: 80% of filtered lithium is reabsorbed in the proximal convoluted tubules; decreased in elderly patients secondary to age-related decreases in renal function (Ward 1994)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48875002\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric patients, great variability in clearance was found across subjects with linear pharmacokinetics correlated to fat-free mass (Findling 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189326\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Lithium Carbonate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $13.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $17.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $36.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lithium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mEq/5 mL (500 mL): $180.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Lithium Carbonate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $46.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 mg (100): $50.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Lithobid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $1,275.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Lithium Carbonate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $21.52</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189329\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Calith (TW);</li>\n      <li>Camcolit (BE, BH, CY, EG, IE, IQ, IR, KW, LB, LU, LY, MT, OM, PK, QA, SA, SG, SY, TW, YE);</li>\n      <li>Camcolite (AE, JO);</li>\n      <li>Carbolim (BR);</li>\n      <li>Carbolit (CL, CO, MX);</li>\n      <li>Carbolithium (IT);</li>\n      <li>Carlit (PY);</li>\n      <li>Ceglution (AR);</li>\n      <li>Contemnol (CZ);</li>\n      <li>Eskalith (BB, BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Frimania (ID);</li>\n      <li>Hynorex Retard (DE);</li>\n      <li>Hypnolith (LK);</li>\n      <li>Karlit (AR);</li>\n      <li>Kilonum (TR);</li>\n      <li>Licab (IN);</li>\n      <li>Licarb (HK, TH);</li>\n      <li>Licarbium (IL);</li>\n      <li>Limas (JP);</li>\n      <li>Liskonum (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Litarex (KW, QA, SA);</li>\n      <li>Litcab (PH);</li>\n      <li>Lithan (KR);</li>\n      <li>Litheum 300 (MX);</li>\n      <li>Lithicarb (AU, MY);</li>\n      <li>Lithicarb FC (NZ);</li>\n      <li>Lithin SR (BD);</li>\n      <li>Lithionit (NO, SE);</li>\n      <li>Lithium Carbonicum (PL);</li>\n      <li>Lithiumkarbonat &rdquo;Oba&rdquo; (DK);</li>\n      <li>Lithocap (IN);</li>\n      <li>Lithosun SR (BD);</li>\n      <li>Litiam ER (BD);</li>\n      <li>Liticarb (HN, HU);</li>\n      <li>Litij-karbonat (HR);</li>\n      <li>Litil (DO);</li>\n      <li>Litiumkarbonat &rdquo;Dak&rdquo; (DK);</li>\n      <li>Lito (FI);</li>\n      <li>Litocarb (PE);</li>\n      <li>Manicarb SR (LK);</li>\n      <li>Maniprex (BE, LU);</li>\n      <li>Microlit (PH);</li>\n      <li>Milithin (GR);</li>\n      <li>Neurolepsin (AT);</li>\n      <li>Plenur (ES);</li>\n      <li>Priadel (BE, GB, IE, LU, NL, NZ, PT, TR);</li>\n      <li>Priadel Retard (CH);</li>\n      <li>Quilonium-R (PH);</li>\n      <li>Quilonorm (AT);</li>\n      <li>Quilonorm Retardtabletten (CH);</li>\n      <li>Quilonum Retard (DE);</li>\n      <li>Quilonum retard (LU);</li>\n      <li>Quilonum SR (AU);</li>\n      <li>Sicolitio (UY);</li>\n      <li>Teralithe (FR);</li>\n      <li>Theralite (CO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,&quot; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Psychiatric Association (APA). Practice guideline for the treatment of patients with bipolar disorder (revision). <i>Am J Psychiatry</i>. 2002;159(4 Suppl):1-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/11958165/pubmed\" target=\"_blank\" id=\"11958165\">11958165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bogen DL, Sit D, Genovese A, et al, &quot;Three Cases of Lithium Exposure and Exclusive Breastfeeding,&quot; <i>Arch Womens Ment Health</i>, 2012, 15(1):69-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/22277970/pubmed\" target=\"_blank\" id=\"22277970\">22277970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broome JT, Solorzano CC. Lithium use and primary hyperparathyroidism. <i>Endocr Pract</i>. 2011;17(Suppl 1):31-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/21247849/pubmed\" target=\"_blank\" id=\"21247849\">21247849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campbell M, Adams PB, Small AM, et al, &ldquo;Lithium in Hospitalized Aggressive Children With Conduct Disorder: A Double-Blind and Placebo-Controlled Study,&rdquo; <i>J Am Acad Child Adolesc Psychiatry</i>, 1995, 34(4):445-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/7751258 /pubmed\" target=\"_blank\" id=\"7751258 \">7751258 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campbell M, Kafantaris V, and Cueva JE, &ldquo;An Update on the Use of Lithium Carbonate in Aggressive Children and Adolescents With Conduct Disorder,&rdquo; <i>Psychopharmacol Bull</i>, 1995a, 31(1):93-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/7675995/pubmed\" target=\"_blank\" id=\"7675995\">7675995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Findling RL, Kafantaris V, Pavuluri M, et al. Dosing strategies for lithium monotherapy in children and adolescents with bipolar I disorder. <i>J Child Adolesc Psychopharmacol</i>. 2011;21(3):195-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/21663422/pubmed\" target=\"_blank\" id=\"21663422\">21663422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Findling RL, Kafantaris V, Pavuluri M, et al. Post-acute effectiveness of lithium in pediatric bipolar I disorder. <i>J Child Adolesc Psychopharmacol</i>. 2013;23(2):80-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/23510444/pubmed\" target=\"_blank\" id=\"23510444\">23510444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Findling RL, Landersdorfer CB, Kafantaris V, et al. First-dose pharmacokinetics of lithium carbonate in children and adolescents. <i>J Clin Psychopharmacol</i>. 2010;30(4):404-410.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/20531219/pubmed\" target=\"_blank\" id=\"20531219\">20531219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Findling RL, Robb A, McNamara NK, et al. Lithium in the acute treatment of bipolar I disorder: A double-blind, placebo-controlled study. <i>Pediatrics</i>. 2015;136(5):885-894.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/26459650/pubmed\" target=\"_blank\" id=\"26459650\">26459650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flaherty B and Krenzelok EP, &quot;Neonatal Lithium Toxicity as a Result of Maternal Toxicity,&quot; <i>Vet Hum Toxicol</i>, 1997, 39(2):92-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/9080635/pubmed\" target=\"_blank\" id=\"9080635\">9080635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gracious BL, Findling RL, Seman C, Youngstrom EA, Demeter CA, Calabrese JR. Elevated thyrotropin in bipolar youths prescribed both lithium and divalproex sodium. <i>J Am Acad Child Adolesc Psychiatry</i>. 2004;43(2):215-220.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/14726729/pubmed\" target=\"_blank\" id=\"14726729\">14726729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grandjean EM and Aubry JM, &quot;Lithium: Updated Human Knowledge Using an Evidence-Based Approach: Part III: Clinical Safety,&quot; <i>CNS Drugs</i>, 2009, 23(5):397-418.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/19453201/pubmed\" target=\"_blank\" id=\"19453201\">19453201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: what do we know? <i>J Affect Disord</i>. 2013;146(2):151-157.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/22985484/pubmed\" target=\"_blank\" id=\"22985484\">22985484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malone RP, Delaney MA, Luebbert JF, et al, &ldquo;A Double-Blind Placebo-Controlled Study of Lithium in Hospitalized Aggressive Children and Adolescents With Conduct Disorder,&rdquo; <i>Arch Gen Psychiatry</i>, 2000, 57(7):649-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/10891035/pubmed\" target=\"_blank\" id=\"10891035\">10891035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Newport DJ, Viguera AC, Beach AJ, et al, &quot;Lithium Placental Passage and Obstetrical Outcome: Implications for Clinical Management During Late Pregnancy,&quot; <i>Am J Psychiatry</i>, 2005, 162(11):2162-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/16263858/pubmed\" target=\"_blank\" id=\"16263858\">16263858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel NC, DelBello MP, Bryan HS, et al. Open-label lithium for the treatment of adolescents with bipolar depression. <i>J Am Acad Child Adolesc Psychiatry</i>. 2006;45(3):289-297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/16540813/pubmed\" target=\"_blank\" id=\"16540813\">16540813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanacora G. New understanding of mechanisms of action of bipolar medications. <i>J Clin Psychiatry</i>. 2008;69(suppl 5):22-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/19265637/pubmed\" target=\"_blank\" id=\"19265637\">19265637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sharma V, Burt VK, and Ritchie HL, &quot;Bipolar II Postpartum Depression: Detection, Diagnosis, and Treatment,&quot; <i>Am J Psychiatry</i>, 2009, 166(11):1217-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/19884236/pubmed\" target=\"_blank\" id=\"19884236\">19884236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viguera AC, Newport DJ, Ritchie J, et al, &quot;Lithium in Breast Milk and Nursing Infants: Clinical Implications,&quot; <i>Am J Psychiatry</i>, 2007, 164(2):342-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/17267800/pubmed\" target=\"_blank\" id=\"17267800\">17267800</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ward ME, Musa MN, Bailey L. Clinical pharmacokinetics of lithium. <i>J Clin Pharmacol</i>. 1994;34(4):280-285.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/8006194/pubmed\" target=\"_blank\" id=\"8006194\">8006194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weller EB, Weller RA, and Fristad MA, &ldquo;Lithium Dosage Guide for Prepubertal Children: A Preliminary Report,&rdquo; <i>J Am Acad Child Psychiatry</i>, 1986, 25(1):92-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/3081617/pubmed\" target=\"_blank\" id=\"3081617\">3081617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yonkers KA, Vigod S, and Ross LE, &quot;Diagnosis, Pathophysiology, and Management of Mood Disorders in Pregnant and Postpartum Women,&quot; <i>Obstet Gynecol</i>, 2011, 117(4):961-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/21422871/pubmed\" target=\"_blank\" id=\"21422871\">21422871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lithium-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12559 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709018\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520178\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F189344\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053683\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053675\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F189316\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F189302\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053688\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25226298\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053687\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F189394\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F189392\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F189324\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F189306\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F48857646\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299613\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F189311\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F189312\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F189327\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053682\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1053686\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F189305\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F189323\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F48875002\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F189326\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F189329\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12559|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lithium-drug-information\" class=\"drug drug_general\">Lithium: Drug information</a></li><li><a href=\"topic.htm?path=lithium-patient-drug-information\" class=\"drug drug_patient\">Lithium: Patient drug information</a></li></ul></div></div>","javascript":null}